Boston Biomedica Sells Diagnostics and Biotech Divisions

The sale of substantially all of the assets and selected liabilities of the BBI Diagnostics and BBI Biotech divisions of Boston Biomedica (West Bridgewater, MA, USA) have been sold to SeraCare Life Sciences, Inc. (Oceanside, CA, USA) for U.S.$30 million in cash, plus the assumption of certain liabilities. Boston Biomedica has changed its name to Pressure BioSciences, Inc. (PBI).

¡°This transaction also enables Pressure BioSciences to focus our efforts on our novel pressure cycling activities (PCT),¡± commented Richard T. Schumacher, president and CEO of Pressure BioSciences. ¡°To this end, we continue to plan for the commercial release of our new bench top PCT instrument by the end of the year, to collaborate with leading researchers and laboratories throughout North America in their use of PCT to generate important data in the areas of genomics and proteomics, and to expand our already strong PCT intellectual property portfolio.¡±

PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions. Applications range from genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, and protein purification. PBI holds 13 U.S. and foreign patents covering multiple applications of PCT in the life sciences field.



Related Links:
Pressure BioSciences
SeraCare